PharmExec Blog
Follow Us
RSS
Bookstore
Author Archives: Jill Wechsler
IOM: Curb Fake Meds through Track-and-Trace, but Forget "Counterfeits"
A new report from the Institute of Medicine (IOM) has drawn a lot of attention to the public health dangers of falsified and substandard medicines around the world. The aim is to build support for a range of activities that can limit the spread of fake medicines in the U.S. and help developing nations strengthen [...]
Tom Abrams: Caronia Won't Stop Off-Label Enforcement
The much-discussed US v. Caronia case, which has raised questions about the Food and Drug Administration prosecution of pharma companies for making off-label product claims, doesn’t change very much, according to FDA’s top drug marketing enforcer.
Posted in Advertising, Agency Insight, E-Media, FDA, Legal, Marketing, Regulatory, leadership, social media Tagged CBI, FDA, First Amendment, misbranding, off-label, OPDP, Tom Abrams, US v. Caronia 1 Comment
Pharma Pricing Top Target for Medicare Cutbacks
In the dog-eat-dog world of federal deficit reduction, there seems to be one health-related spending cut with broad bi-partisan support: require drug companies to give the federal government “a better deal on medications for low-income people on Medicare.” Nearly 70% of respondents back this strategy, according to a survey sponsored by the Kaiser Family Foundation [...]
UN Pact Scuttles Anti-Vaccine Provision
A new international agreement to reduce mercury contamination of air and water was recently adopted by 140 countries, without a proposal that threatened to limit access to vaccines in much of the world. The credit goes to public health authorities and medical experts who challenged a provision blocking production of vaccines with the preservative thimerosal, [...]
Posted in Emerging Markets, FDA, Global, Legal, Market Access, Patient Communication, Safety, healthcare Tagged autism, developing countries, patient advocates, patient groups, thimerosol, vaccines, WHO 1 Comment
Part D Politics: Medicare Drug Rebates or Price Controls?